Dr. Richard Rosenfeld Named One of the World’s Top Experts in Otitis Media

Jan 30, 2014

Brooklyn, NY – Richard Rosenfeld, MD, MPH, professor and chair of otolaryngology at SUNY Downstate Health Sciences University, has been named one the world’s top medical specialists in the research and treatment of otitis media by Expertscape, a medical search and content service that enables healthcare consumers and medical professionals to identify and research medical experts.

Otitis media is both the most common and most easily treated type of ear infection in children. However, in the 20-30% of all children who experience recurrent episodes or persistent symptoms, diagnosis and treatment become more complex, in some cases warranting a second opinion from someone with special interest in otitis media. Dr. Rosenfeld was one of nine medical experts identified by Expertscape from institutions around the world. Expertscape defines an expert as someone who has published peer-reviewed research in the science, therapies, and complications for a specific medical topic.

In addition to his position at SUNY Downstate, Dr. Rosenfeld is editor-in-chief of Otolaryngology – Head and Neck Surgery.  He graduated from the Otolaryngology Residency Program at Mount Sinai Medical Center and then completed a two-year fellowship in pediatric otolaryngology at Children’s Hospital of Pittsburgh with a Master’s Degree in Public Health.

He has received the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Distinguished Service Award three times, the Society for Ear, Nose and Throat Advances in Children (SENTAC) Robert Ruben Award for Excellence in Pediatric Otolaryngology, and the Interamerican Association of Pediatric Otorhinolaryngology (IAPO) Award for Worldwide Contributions to Pediatric Otolaryngology.  Dr. Rosenfeld is the senior advisor for guidelines and quality at AAO-HNS and has chaired numerous national committees at the AAO-HNS and the American Society of Pediatric Otolaryngology (ASPO).

He is the author, coauthor, or editor of five books and more than 260 scientific publications and textbook chapters, including chapters in Bailey's Head and Neck Surgery: Otolaryngology and Cummings Otolaryngology - Head and Neck Surgery on understanding data and medical literature.  Dr. Rosenfeld has given more than 600 scientific presentations and is an international authority on guideline development and evidence-based medicine, in addition to otitis media.  He is president of the International Society for Otitis Media (ISOM), past-president of ASPO, and serves on the Board of Directors for the AAO-HNS, ASPO, Guideline International Network, ISOM, and the Auditory-Oral School of Brooklyn.  Dr. Rosenfeld has been listed in Best Doctors in America and in “Best Doctors in New York” in New York magazine since 1996.


About SUNY Downstate Health Sciences University

Downstate Health Sciences University in Brooklyn is one of four academic health centers (AMCs) in The State University of New York (SUNY) 64-campus system and the only SUNY AMC in New York City dedicated to health education, research, and patient care for the borough’s 2.7 million residents. Its flagship hospital, University Hospital at Downstate (UHD), is a teaching hospital and benefits from the expertise of Downstate’s exceptional medical school and world-class academic center research facilities. With a staff of over 800 physicians representing 53 specialties and subspecialties, Downstate offers comprehensive healthcare services to the community.

UHD provides high-risk neonatal and infant services, pediatric nephrology, and dialysis for kidney diseases and is the only kidney transplantation program in Brooklyn. Beyond its clinical expertise, Downstate houses a range of esteemed educational institutions, including its College of Medicine, College of Nursing, School of Health Professions, School of Graduate Studies, and School of Public Health. Downstate fosters innovation through its multifaceted biotechnology initiative, the Biotechnology Incubator and BioBAT, which support early-stage and more mature biotech companies.